Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

MTY Food Group Inc. Announces Results from 2025 Annual General Meeting

MONTREAL, May 05, 2025 (GLOBE NEWSWIRE) -- MTY Food Group Inc. (“MTY” or the “Company”) (TSX: MTY), franchisor and operator of multiple concepts of restaurants, is pleased to report the results from the votes from its shareholders for the 2025 Annual General Meeting of …

EODHD | 05 May 2025

Sunoco LP to Acquire Parkland Corporation in Transaction Valued at $9.1 Billion

DALLAS, May 5, 2025 /PRNewswire/ -- Sunoco LP (NYSE: SUN) ("Sunoco" or the "Partnership") and Parkland Corporation (TSX: PKI) ("Parkland") announced today that the parties have entered into a definitive agreement whereby Sunoco will acquire all outstanding shares of Parkland in a cash and …

EODHD | 05 May 2025

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

BioCryst Pharmaceuticals, Inc. —Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays …

EODHD | 05 May 2025

Selarsdi hliðstæðan fær fullan útskiptileika við frumlyfið Stelara í Bandaríkjunum

Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hefur heimilað sölu Selarsdi með útskiptileika við frumlyfið við Stelara, fyrir öll lyfjaform og ábendingar frumlyfsins, frá og með 30. apríl sl. Selarsdi hefur verið á markaði í Bandaríkjunum frá 21. febrúar sl. Eins og frumlyfið er Selarsdi heimilað …

EODHD | 05 May 2025

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Alvotech The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approvedfor all indicationsmatching the reference product SELARSDI is indicatedfor the treatment of moderate …

EODHD | 05 May 2025

Stock Market Selloff: 4 No-Brainer Stocks to Buy Right Now

Key Points Broadcom’s custom AI chips and strong networking infrastructure are in high demand from hyperscalers. Despite elevated trade war concerns, Shopify’s diversified and resilient business model makes it attractive. Vertex Pharmaceuticals and Intuitive Surgical are both sound picks within the healthcare arena. In …

EODHD | 05 May 2025

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Axsome Therapeutics, Inc. Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO® approved …

EODHD | 05 May 2025

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-class, potent classical pathway inhibitor intended as …

EODHD | 05 May 2025

GXO and Blue Yonder Announce New Strategic Global Agreement

New agreement creates strategic growth opportunities for both companies while delivering industry-leading supply chain solutions for customers GREENWICH, Conn. and DALLAS, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, and Blue Yonder, the …

EODHD | 05 May 2025

Pershing Square to Invest $900 million to Acquire Nine Million Newly Issued Shares of Howard Hughes Holdings and Transform HHH Into a Diversified Holding Company

Pershing Square to Support HHH’s Strategic Expansion Through Investment, Advisory, and Other Resources HHH Will Operate as a Diversified Holding Company Seeking to Acquire Controlling Interests in High-Quality, Durable Growth Public and Private Companies Howard Hughes Corporation, HHH’s Real Estate Development Business and Principal …

EODHD | 05 May 2025
Support

Hi! How can we help you today?

Loading…